Literature DB >> 26237009

Models to Study NK Cell Biology and Possible Clinical Application.

Anthony E Zamora1, Steven K Grossenbacher1, Ethan G Aguilar1, William J Murphy1,2.   

Abstract

Natural killer (NK) cells are large granular lymphocytes of the innate immune system, responsible for direct targeting and killing of both virally infected and transformed cells. NK cells rapidly recognize and respond to abnormal cells in the absence of prior sensitization due to their wide array of germline-encoded inhibitory and activating receptors, which differs from the receptor diversity found in B and T lymphocytes that is due to the use of recombination-activation gene (RAG) enzymes. Although NK cells have traditionally been described as natural killers that provide a first line of defense prior to the induction of adaptive immunity, a more complex view of NK cells is beginning to emerge, indicating they may also function in various immunoregulatory roles and have the capacity to shape adaptive immune responses. With the growing appreciation for the diverse functions of NK cells, and recent technological advancements that allow for a more in-depth understanding of NK cell biology, we can now begin to explore new ways to manipulate NK cells to increase their clinical utility. In this overview unit, we introduce the reader to various aspects of NK cell biology by reviewing topics ranging from NK cell diversity and function, mouse models, and the roles of NK cells in health and disease, to potential clinical applications. © 2015 by John Wiley & Sons, Inc.
Copyright © 2015 John Wiley & Sons, Inc.

Entities:  

Keywords:  NK cell biology; clinical application; mouse models; natural killer cells

Mesh:

Substances:

Year:  2015        PMID: 26237009      PMCID: PMC4772895          DOI: 10.1002/0471142735.im1437s110

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN: 1934-3671


  34 in total

Review 1.  Natural killer cell developmental pathways: a question of balance.

Authors:  James P Di Santo
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

2.  Expression of major histocompatibility complex class I-related chain A/B (MICA/B) in pancreatic carcinoma.

Authors:  Zilvinas Dambrauskas; Helena Svensson; Meghnad Joshi; Anders Hyltander; Peter Naredi; Britt-Marie Iresjö
Journal:  Int J Oncol       Date:  2013-10-31       Impact factor: 5.650

Review 3.  NK cell development, homeostasis and function: parallels with CD8⁺ T cells.

Authors:  Joseph C Sun; Lewis L Lanier
Journal:  Nat Rev Immunol       Date:  2011-08-26       Impact factor: 53.106

4.  "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype.

Authors:  R Kiessling; E Klein; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

5.  Immune responses in interleukin-2-deficient mice.

Authors:  T M Kündig; H Schorle; M F Bachmann; H Hengartner; R M Zinkernagel; I Horak
Journal:  Science       Date:  1993-11-12       Impact factor: 47.728

6.  Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain.

Authors:  J P DiSanto; W Müller; D Guy-Grand; A Fischer; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

7.  Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain.

Authors:  H Suzuki; G S Duncan; H Takimoto; T W Mak
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

8.  Defective lysosomal enzyme secretion in kidneys of Chediak-Higashi (beige) mice.

Authors:  E J Brandt; R W Elliott; R T Swank
Journal:  J Cell Biol       Date:  1975-12       Impact factor: 10.539

9.  Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.

Authors:  Laurent Boissel; Monica Betancur-Boissel; Weiquan Lu; Daniela S Krause; Richard A Van Etten; Winfried S Wels; Hans Klingemann
Journal:  Oncoimmunology       Date:  2013-10-22       Impact factor: 8.110

10.  Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice.

Authors:  G Cudkowicz; M Bennett
Journal:  J Exp Med       Date:  1971-12-01       Impact factor: 14.307

View more
  12 in total

1.  CD8+ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy.

Authors:  Jillian Rosenberg; Jun Huang
Journal:  Curr Opin Chem Eng       Date:  2017-12-14       Impact factor: 5.163

2.  NK cells for PD-1/PD-L1 blockade immunotherapy: pinning down the NK cell.

Authors:  Cordelia Dunai; William J Murphy
Journal:  J Clin Invest       Date:  2018-09-10       Impact factor: 14.808

Review 3.  Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy.

Authors:  Jesus I Luna; Steven K Grossenbacher; William J Murphy; Robert J Canter
Journal:  Expert Opin Biol Ther       Date:  2016-12-23       Impact factor: 4.388

Review 4.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

5.  Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease.

Authors:  Martina Bonacini; Alessandra Soriano; Alessandro Zerbini; Eleonora Calò; Luca Cimino; Francesco Muratore; Luigi Fontana; Luca Braglia; Maria Parmeggiani; Carlo Salvarani; Stefania Croci
Journal:  Front Immunol       Date:  2018-09-25       Impact factor: 7.561

Review 6.  Natural Killer Cells: Development, Maturation, and Clinical Utilization.

Authors:  Alex M Abel; Chao Yang; Monica S Thakar; Subramaniam Malarkannan
Journal:  Front Immunol       Date:  2018-08-13       Impact factor: 7.561

Review 7.  Stem Cell-Based Disease Models for Inborn Errors of Immunity.

Authors:  Aline Zbinden; Kirsten Canté-Barrett; Karin Pike-Overzet; Frank J T Staal
Journal:  Cells       Date:  2021-12-30       Impact factor: 6.600

Review 8.  Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19.

Authors:  Madhan Jeyaraman; Sathish Muthu; Asawari Bapat; Rashmi Jain; E S Sushmitha; Arun Gulati; Talagavadi Channaiah Anudeep; Shirodkar Jaswandi Dilip; Niraj Kumar Jha; Dhruv Kumar; Kavindra Kumar Kesari; Shreesh Ojha; Sunny Dholpuria; Gaurav Gupta; Harish Dureja; Dinesh Kumar Chellappan; Sachin Kumar Singh; Kamal Dua; Saurabh Kumar Jha
Journal:  Heliyon       Date:  2021-07-21

9.  Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.

Authors:  Masayuki Shiozawa; Chuan-Hsin Chang; Yi-Chun Huang; Yi-Ching Chen; Mau-Shin Chi; Hsu-Chao Hao; Yue-Cune Chang; Satoru Takeda; Kwan-Hwa Chi; Yu-Shan Wang
Journal:  BMC Immunol       Date:  2018-08-03       Impact factor: 3.615

Review 10.  Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.

Authors:  Yuqing Cao; Xiaoyu Wang; Tianqiang Jin; Yu Tian; Chaoliu Dai; Crystal Widarma; Rui Song; Feng Xu
Journal:  Signal Transduct Target Ther       Date:  2020-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.